Pluri (PLUR) Stock Jumps 9% on US Patent for Immune Cell Production
Monday, 8 April 2024, 14:35
Pluri (PLUR) Stock Surges 9% on US Patent
Pluri (PLUR) stock witnessed a 9% increase after the Israeli biotech firm successfully obtained a US patent for its groundbreaking immune cell production technique.
Key Highlights:
- Surge in Stock Price: Pluri (PLUR) stock rose by 9% following the US patent approval.
- Market Impact: Investors responded positively to the news, reflecting growing confidence in Pluri's technology.
- Innovative Technology: The patented immune cell production process has solidified Pluri's position in the biotech sector.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.